American Society of Hirudotherapy

Management options for pediatric venous thromboembolic disease: Beyond anticoagulation with endovascular therapies.

Review published in Thrombosis research (2024)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsDrug DevelopmentMitta et al. · Thrombosis research, 2024

Abstract

Venous thromboembolism (VTE) in pediatric patients is an uncommon but serious diagnosis that has an array of therapeutic options and challenges. An assessment of the existing literature on management of pediatric patients with VTE was conducted. The interventions reviewed include anticoagulation, thrombolysis, thrombectomy, inferior vena cava (IVC) filters, and venous stenting. For each intervention, a discussion of mechanism of action, indications, contraindications, and potential complications was performed. While anticoagulants are considered the first-line pediatric VTE treatment, many drugs remain investigational in this patient population and treatment recommendations are extrapolated from adult practice. Thrombolysis may be indicated in cases of acute thrombosis requiring more rapid clot resolution but presents a greater bleeding risk than anticoagulation. Similarly, thrombectomy also provides rapid clot resolution and offers a larger therapeutic window and usage in more mature thrombi than thrombolysis. In select patient groups, IVC filters may be indicated in the prevention of PE but present with inherent thrombogenicity and risk of migration. The data regarding pediatric VTE treatment options, monitoring, and long term outcomes is limited compared to the adult population. The relatively few clinical trials including pediatric patients have a relatively small sample size and are heterogenous with regards to predisposing factors that further exacerbate generalizability. Additional research is needed to help construct and evaluate a robust treatment algorithm for pediatric patients with VTE.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansVenous ThromboembolismAnticoagulantsChildEndovascular ProceduresThrombolytic TherapyThrombectomyVena Cava Filters

Summary

Venous thromboembolism (VTE) in pediatric patients is an uncommon but serious diagnosis that has an array of therapeutic options and challenges. An assessment of the existing literature on management of pediatric patients with VTE was conducted.

Why This Matters for Hirudotherapy

This review assesses the existing literature on management of pediatric venous thromboembolic disease, including anticoagulation, thrombolysis, thrombectomy, inferior vena cava filters, and venous stenting, with discussion of mechanisms, indications, contraindications, and complications for each. The authors note that while anticoagulants are first-line treatment, many drugs remain investigational in pediatric populations and data on monitoring and long-term outcomes is limited. The abstract contains no mention of leeches, hirudotherapy, leech-derived compounds, or the leech secretome. There is no defensible connection to ASH's domain, as the review evaluates conventional endovascular therapies and pharmaceutical agents exclusively.

Citation

Management options for pediatric venous thromboembolic disease: Beyond anticoagulation with endovascular therapies.

Mitta et al. · Thrombosis research, 2024

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.